Rhumbline Advisers Catalyst Pharmaceuticals, Inc. Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q4 2024

A detailed history of Rhumbline Advisers transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 312,320 shares of CPRX stock, worth $7.26 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
312,320
Previous 311,368 0.31%
Holding current value
$7.26 Million
Previous $6.19 Million 5.32%
% of portfolio
0.01%
Previous 0.01%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 30, 2025
BUY
$19.73 - $23.93 $18,782 - $22,781
952 Added 0.31%
312,320 $6.52 Million
Q3 2024

Nov 12, 2024
SELL
$15.19 - $21.35 $188,371 - $264,761
-12,401 Reduced 3.83%
311,368 $6.19 Million
Q2 2024

Aug 01, 2024
BUY
$14.68 - $16.92 $158,617 - $182,820
10,805 Added 3.45%
323,769 $5.02 Million
Q1 2024

May 09, 2024
BUY
$13.18 - $17.11 $316,886 - $411,375
24,043 Added 8.32%
312,964 $4.99 Million
Q4 2023

Feb 08, 2024
SELL
$11.78 - $17.29 $38,461 - $56,451
-3,265 Reduced 1.12%
288,921 $4.86 Million
Q3 2023

Nov 09, 2023
BUY
$11.69 - $15.02 $54,054 - $69,452
4,624 Added 1.61%
292,186 $3.42 Million
Q2 2023

Aug 08, 2023
BUY
$11.5 - $18.08 $77,981 - $122,600
6,781 Added 2.42%
287,562 $3.86 Million
Q1 2023

May 11, 2023
BUY
$14.34 - $21.05 $235,749 - $346,062
16,440 Added 6.22%
280,781 $4.66 Million
Q4 2022

Feb 14, 2023
BUY
$12.25 - $19.5 $73,990 - $117,780
6,040 Added 2.34%
264,341 $4.92 Million
Q3 2022

Nov 10, 2022
BUY
$7.06 - $15.52 $1.04 Million - $2.29 Million
147,517 Added 133.16%
258,301 $3.31 Million
Q2 2022

Aug 11, 2022
SELL
$6.23 - $8.57 $106,962 - $147,138
-17,169 Reduced 13.42%
110,784 $777,000
Q1 2022

May 12, 2022
SELL
$5.31 - $8.31 $109,014 - $170,604
-20,530 Reduced 13.83%
127,953 $1.06 Million
Q4 2021

Feb 10, 2022
SELL
$5.21 - $7.45 $5,673 - $8,113
-1,089 Reduced 0.73%
148,483 $1.01 Million
Q3 2021

Nov 12, 2021
BUY
$4.85 - $6.04 $10,577 - $13,173
2,181 Added 1.48%
149,572 $793,000
Q2 2021

Aug 05, 2021
BUY
$4.29 - $6.05 $119,455 - $168,462
27,845 Added 23.29%
147,391 $847,000
Q1 2021

May 06, 2021
SELL
$3.45 - $4.69 $23,253 - $31,610
-6,740 Reduced 5.34%
119,546 $551,000
Q4 2020

Feb 10, 2021
BUY
$2.97 - $3.83 $21,176 - $27,307
7,130 Added 5.98%
126,286 $422,000
Q3 2020

Nov 12, 2020
SELL
$2.97 - $5.08 $49,910 - $85,369
-16,805 Reduced 12.36%
119,156 $354,000
Q2 2020

Aug 13, 2020
BUY
$3.48 - $5.05 $33,759 - $48,990
9,701 Added 7.68%
135,961 $628,000
Q1 2020

May 06, 2020
BUY
$2.61 - $5.21 $300 - $599
115 Added 0.09%
126,260 $486,000
Q4 2019

Feb 05, 2020
BUY
$3.67 - $5.7 $2,763 - $4,292
753 Added 0.6%
126,145 $473,000
Q3 2019

Oct 23, 2019
SELL
$3.89 - $7.43 $3,073 - $5,869
-790 Reduced 0.63%
125,392 $666,000
Q2 2019

Aug 14, 2019
BUY
$2.7 - $6.11 $7,929 - $17,945
2,937 Added 2.38%
126,182 $485,000
Q1 2019

May 01, 2019
SELL
$2.11 - $5.33 $7,287 - $18,409
-3,454 Reduced 2.73%
123,245 $629,000
Q4 2018

Jan 31, 2019
BUY
$1.92 - $3.62 $81,022 - $152,760
42,199 Added 49.94%
126,699 $243,000
Q3 2018

Nov 07, 2018
SELL
$2.81 - $3.78 $17,492 - $23,530
-6,225 Reduced 6.86%
84,500 $319,000
Q2 2018

Aug 06, 2018
BUY
$2.26 - $3.84 $52,845 - $89,790
23,383 Added 34.72%
90,725 $283,000
Q1 2018

May 02, 2018
BUY
$2.39 - $4.01 $11,531 - $19,348
4,825 Added 7.72%
67,342 $161,000
Q4 2017

Feb 09, 2018
SELL
$2.51 - $4.4 $35,840 - $62,827
-14,279 Reduced 18.59%
62,517 $244,000
Q3 2017

Nov 06, 2017
BUY
$2.4 - $2.94 $184,310 - $225,780
76,796
76,796 $194,000

Others Institutions Holding CPRX

# of Institutions
345
Shares Held
102M
Call Options Held
7.7K
Put Options Held
15.4K
View Full List

About CATALYST PHARMACEUTICALS, INC.

CPRX Quotes by TradingView
  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.39B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email